LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

LLY

1,076.73

-2.38%↓

JNJ

222.23

-1.31%↓

ABBV

211.54

-2.95%↓

UNH

377.82

-0.22%↓

MRK

114.45

-3.5%↓

Strona główna・Stock List・Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals Inc

Open

SectorHealthcare

3.68 3.08

Buy Sell

Overview

Share price change

24h

Current

Min

3.45

Max

3.68

Key metrics
By Trading Economics
Income	-9.4M -118M
Sales	-29M 6.5M
EPS	-0.22
Profit margin	-1,815.575
Employees	600
EBITDA	-20M -109M

Recommendations
By TipRanks
Recommendations	Buy
12 Months Forecast	+105.57% upside

Dividends
By Dow Jones
Next Earnings	4 sie 2026

Market Stats
By TradingEconomics
Market Cap	-270M 1.6B
Previous open	0.6
Previous close	3.68

News Sentiment

By Acuity

100%

320 / 344 Ranking in Healthcare

Recursion Pharmaceuticals Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

19 lut 2026, 21:28 UTC

Acquisitions, Mergers, Takeovers

Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street. -- Barrons.com

19 lut 2026, 10:27 UTC

Acquisitions, Mergers, Takeovers

Nvidia Dumped It, Cathie Wood Snapped It Up. This Pharma Stock Is Splitting Wall Street. -- Barrons.com

18 lut 2026, 14:52 UTC

Acquisitions, Mergers, Takeovers

Applied Digital, Recursion Pharmaceuticals Stocks Drop. Blame Nvidia. -- Barrons.com

Peer Comparison

Price change

Recursion Pharmaceuticals Inc Forecast

Price Target

By TipRanks

105.57% upside

12 Months Forecast

Average 7.38 USD 105.57%

High 10 USD

Low 5.5 USD

Based on 5 Wall Street analysts offering 12 month price targets forRecursion Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

5 ratings

Buy

Hold

Sell

Based on 5 analysts giving stock ratings to Recursion Pharmaceuticals Inc - Dist in the past 3 months.

Sentiment

By Acuity

320 / 344 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Recursion Pharmaceuticals Inc

Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers. Its preclinical stage product includes RBM39 to treat HR-proficient ovarian cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Roche & Genentech; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.